EGFR and neoplasm: Of all cut-off values used in this study, only the EGFR positive immunostaining at cut-off values of >5% and >10% of the tumour cells were significantly associated with a poorer disease-free survival (32.34 ± 4.88 vs 53.79 ± 5.78 months, p = 0.014 Figure 2B) and (29.64 ± 4.86 vs 47.9 ± 5.05 months, p = 0.026, data not shown).